• 1
    Wall ME, Wani MC. Camptothecin. Discovery to clinic. Ann N Y Acad Sci. 1996; 803: 1-12.
  • 2
    Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997; 33: 245-259.
  • 3
    Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following IV infusion of [C]CPT-11 in cancer patients. Drug Metab Dispos. 2000; 28: 423-433.
  • 4
    Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos. 1997; 25: 1157-1164.
  • 5
    Lokiec F, Canal P, Gay C, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol. 1995; 36: 79-82.
  • 6
    Sapra P, Zhao H, Mehlig M, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14: 1888-1896.
  • 7
    Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 2002; 62: 3138-3143.
  • 8
    Okuda T, Kawakami S, Akimoto N, Niidome T, Yamashita F, Hashida M. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release. 2006; 116: 330-336.
  • 9
    Zhao H, Rubio B, Sapra P, et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem. 2008; 19: 849-859.
  • 10
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 11
    Omura GA. Modified Fibonacci search [letter]. J Clin Oncol. 2003; 21: 3177.
  • 12
    Deylon B, Lavielle M, Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann Stat. 1999; 27: 94-128.
  • 13
    Kuhn E, Lavielle M. Coupling a stochastic approximation version of EM with a MCMC procedure. Esaim Probab Stat. 2004; 8: 115-131.
  • 14
    O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006; 24: 4534-4538.
  • 15
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 16
    de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist. 2006; 11: 944-954.
  • 17
    McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol. 2004; 22: 1356-1359.
  • 18
    Camptosar (irinotecan hydrochloride injection) [package insert]. New York: Pfizer Inc.; 2006.
  • 19
    Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 866-871.
  • 20
    Patnaik A, Papadopoulos K, Beeram M, et al. EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase 1 dose-escalation study [abstract]. Mol Cancer Ther. 2009; 8: C221.